首页 | 本学科首页   官方微博 | 高级检索  
检索        

骨形态发生蛋白2/聚乳酸缓释微球的制备及表征
引用本文:马立坤,叶鹏,黄文良,田仁元,邓江.骨形态发生蛋白2/聚乳酸缓释微球的制备及表征[J].中国临床康复,2014(3):395-400.
作者姓名:马立坤  叶鹏  黄文良  田仁元  邓江
作者单位:遵义医学院第三附属医院骨一科,贵州省遵义市563000
基金项目:贵州省省长基金项目(2011(25)),项目名称:rhBMP-2缓释系统/自体松质骨复合生物支架修复骨缺损的研究;贵州省科学技术基金项目(黔科合SY[2010]3101),项目名称:SF-CS-nHA支架与基因修饰后BMSCs构建人工骨种植体的成骨作用研究;遵义市科技局、遵义医院联合科研项目(遵义市科合社字[2010]015号),项目名称:RGD表面修饰SF/CS/n-HA材料复合携带目的基因的BMSCs成骨性能研究
摘    要:背景:聚乳酸具有良好的生物相容性,是优良的药物缓释载体。 目的:制备重组人骨形态发生蛋白2/聚乳酸缓释微球,考察其理化特性。 方法:采用复乳溶剂挥发法制备重组人骨形态发生蛋白2/聚乳酸缓释微球,进行扫描电镜、激光粒度、Zeta电位、溶胀性能检测及采用ELISA试剂盒检测包封率、载药率及体外释药率。 结果与结论:扫描电镜见重组人骨形态发生蛋白2/聚乳酸缓释微球微球近似圆形,形态较规则,分散性较好,表面光滑。激光粒度分析重组人骨形态发生蛋白2/聚乳酸缓释微球微平均粒径839.6 nm,Zeta电位(-32.93±3.74)mV,微球溶胀系数1.157±0.059,包封率及载药率分别为(88.943±2.878)%,(0.026±0.001)%;微球在第1天释药约10.199%,随后释药较恒定,至第19天累计释药率为54.643%。说明制备出的重组人骨形态发生蛋白2/聚乳酸缓释微球的粒径达到中华人民共和国药典第10版二部关于亚微球的定义标准及包封率不低于80%的要求,并且在体外具有很好的缓释功能。

关 键 词:生物材料  缓释材料  重组人骨形态发生蛋白2  聚乳酸  缓释微球  包封率  载药率

Preparation and characterization of recombinant human bone morphogenetic protein-2/ poly lactic acid sustained release microspheres
Ma Li-kun,Ye Peng,Huang Wen-liang,Tian Ren-yuan,Deng Jiang.Preparation and characterization of recombinant human bone morphogenetic protein-2/ poly lactic acid sustained release microspheres[J].Chinese Journal of Clinical Rehabilitation,2014(3):395-400.
Authors:Ma Li-kun  Ye Peng  Huang Wen-liang  Tian Ren-yuan  Deng Jiang
Institution:(First Department of Orthopedics, Third Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China )
Abstract:BACKGROUND: Poly lactic acid as an excellent delivery has good biocompatibility.
OBJECTIVE: To prepare recombinant human bone morphogenetic protein-2 (rhBMP-2)/poly lactic acid (PLA) sustained release microspheres, and to study its physical and chemical properties.
METHODS: The rhBMP-2/PLA sustained release microspheres were prepared using w/o/w solvent evaporation method. Scanning electron microscopy, laser particle size, zeta potential, and swelling properties were detected. ELISA kit was utilized for measurement of encapsulation efficiency, drug-loading rate and in vitro drug release rate.
RESULTS AND CONCLUSION: Under the scanning electron microscope, rhBMP-2/PLA sustained release microspheres were approximately circle with excellent dispersion. The uniform spheres were visible with a mean particle size of 839.6 nm. The zeta potential were (-32.93±3.74) mV. The swelling coefficient was 1.157±0.059. The drug-loading rate and encapsulation efficiency of rhBMP-2/PLA sustained release microspheres were (88.943±2.878)% and (0.026±0.001)% respectively. The drug release rate at 1 day was about 10.199%, then the drug release was relatively constant, and till 19 days, the cumulative drug release rate was 54.643%. These findings indicate that the constructed rhBMP-2/PLA sustained release microspheres meet the requirement of the Chinese Pharmacopoeia (10th edition) that the encapsulation efficiency is not less than 80% and the microspheres have a good slow-release function in vitro.
Keywords:biocompatible materials  bone morphogenetic proteins  lactic acid  microspheres  delayed-action preparations
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号